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Serotonin in the heart: the beauty and the beast  
Existence of a cross-talk between administration of antidepressants targeting serotonin re-uptake 
and its degradation and heart development in foetus has been acknowledged at a terrible price.  The 
use of selective serotonin reuptake inhibitor (SSRI) paroxetine during the first trimester of pregnancy 
was associated with an increased risk in development of heart defects and late first trimester 
spontaneous abortions to which severe heart defects contributed (Sadler, 2011). As the importance 
of serotonin during myocardial development was recognised, pieces of the puzzle began to assemble 
on multiple actions of 5-HT in embryonic and adult heart.  Many of these pieces are still missing.  
From four classes of serotonin receptors, one (5-HT3 receptors) is comprised of ligand-gated ion 
channels, whereas the other three (5-HT1/5, 5-HT2 ad 5-HT4/6/7 receptors) are G protein-coupled 
receptors. 5-HT2B and 5-HT4 receptors are present in the heart.  5-HT2B receptors play an important 
role in cardiac development during embryogenesis, promoting proliferation and differentiation of 
cardiomyoblasts (Nebigil et al., 2000). In adult heart this receptor is involved in progression of 
myocardial hypertrophic remodelling (Nebigil and Maroteaux, 2003). 5-HT4 receptor controls Ca
2+
 
currents through L-type calcium channels and modulates pacemaker currents in atrial myocytes, and, 
when hyperactivated, promotes arrhythmia (Gergs et al., 2010). Antagonists of this receptor are 
tested as antiarrhythmic drugs (Doggrell, 2003).  Apart from receptor-mediated 5-HT signalling, 
hydrogen peroxide produced from serotonin during its degradation inside the cells serves as a 
second messenger or as a damaging pro-oxidant (Cooper et al., 2003). The underlying reactions 
catalyzed by monoamine oxidases (MAO) in the mitochondria of multiple cell types including 
cardiomyocytes (Sivasubramaniam et al., 2003) are: 
 R-CH2NH2 + O2  R-CH=NH + H2O2 
R-CH=NH + H2O  R-CHO + NH3 
Although SSRIs show their beasty look in the first trimester of human life, these drugs appear to give 
the adult heart a helping hand reducing the risk of myocardial infarction (MI)  (Sauer et al., 2001). 
Relief that depressed patients receive after SSRIs administration contributes to an attenuation of 
incidence of MI. But this is not all these drugs do. Serotonin transporters (SERTs) in platelets are also 
supressed by systemic SSRI administration. Platelets are known to take up peripheral serotonin 
which is mainly synthesised by enterochromaffin cells in the gut and release it upon activation 
promoting thereby clot formation. Patients on SSRIs have serotonin-depleted platelets that are not 
capable of facilitating thrombosis (Bismuth-Evenzal et al., 2012). Valve cardiomyocytes are also 
possessing SERT  {Pavone, 2008 #18}. Such a broad range of effects of SSRIs enables these drugs to 
protect the heart from MI, whereas other classes of equally effective antidepressants do not reduce 
the risk of MI (Sauer et al., 2001). 
  
Unfortunately, preventive treatment against MI is hardly possible. Could SSRIs also be viewed as 
attractive candidates for reducing myocardial damage in ischemic or post-MI heart? Do local 
increases in interstitial 5-HT contribute to ischemic heart damage or ischemia-reperfusion injury?  
The study of Sonobe et al (Sonobe et al., 2012) gives us some clues pointing towards active 
regulation of interstitial serotonin levels in rabbit heart in the course of ischemia-reperfusion in vivo. 
The authors used microdialysis technique to monitor 5-HT levels in the interstitial space within the 
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ischemic area of rabbit heart. The impact of 5-HT production, reuptake and degradation on the 
maintenance of serotonin balance was assessed in healthy heart, during ischemic insult and after the 
restoration of coronary blood perfusion. Coronary occlusion was associated with a gradual interstitial 
5-HTaccumulation.  Release of the coronary clamp was followed by an immediate dramatic increase 
in serotonin levels which then declined over the 10-70 min of perfusion. Re-uptake of 5-HT actively 
counteracted its release during reperfusion. Degradation of 5-HT by MAO occurred both during the 
ischemic phase and at reperfusion.  
These findings let one suggest that inhibition of serotonin re-uptake will keep 5-HT4 and 2a  
receptors in cardiomyocytes active promoting most likely positive inotropic effects and sustaining 
contractile function (Levy et al., 2008). However, increased re-uptake of 5-HT by cardiomyocytes 
along with restoration of oxygen supply of the heart muscle provides more fuel to MAO-A, and 
aggravates oxidative stress at reperfusion (Kaludercic et al., 2011). Thus blocking the SERT with SSRI 
including fluoxetine as well as suppressing MAO activity during reperfusion may appear to be very 
beneficial. This therapeutic approach will potentially reduce the risk of re-occluson of coronary 
vessels as 5-HT stores in platelets will be depleted and reduce oxidative stress in myocardial tissue at 
reperfusion rescuing mitochondria from irreversible damage and protecting the tissue from 
reperfusion injury (Ong and Gustafsson, 2012).  Apart from platelets, vagal afferents, and resident 
mast cells cardiomyocytes themselves have been recently shown to express their own 5-HT (Ponicke 
et al., 2012) and possess their own serotonin re-uptake machinery (Pavone et al., 2008). What is the 
impact of this source of 5-HT on the interstitial serotonin pool and if SERT and MAO inhibition 
interfere with 5-HT acting in a paracrine and an autocrine fashion remains to be investigated. The 
study of Sonobe et al. marks the beginning of a long and fascinating journey at the end of which 
knowledge will be transformed into a new treatment strategy. This new strategy will use the strong 
sides of SSRIs avoiding the odds of careless interference with vital physiological actions of 5-HT.        
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